GlassScriptPhysician profile
Cary R Peterson
NPI 1982831558
$3,197.37
in general payments reported to CMS, 2019-2025
29 companies · $648 in 2025
The $648 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.52 · 2020: $43.86 · 2021: $292 · 2022: $408 · 2023: $609 · 2024: $1,097 · 2025: $648.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,354.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,354.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $448.05 | 2022-2025 | |
| Braeburn INC. | $332.35 | 2024-2025 | Brixadi |
| Pfizer INC. | $326.48 | 2023-2025 | |
| Novo Nordisk INC | $261.90 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Biohaven Pharmaceuticals, INC. | $245.41 | 2021 | |
| Lilly USA, LLC | $198.65 | 2022-2024 | Jardiance, Emgality, Zepbound |
| Glaxosmithkline, LLC. | $176.82 | 2022-2025 | Shingrix, Arexvy, Pediarix |
| Incyte Corporation | $119.68 | 2024 | Opzelura |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.43 | 2019-2025 | Jardiance, Synjardy |
| Genentech USA, INC. | $107.41 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $100.97 | 2022 | |
| Amgen INC. | $95.69 | 2022-2024 | Repatha, Otezla |
| E.R. Squibb & Sons, L.L.C. | $78.79 | 2019-2023 | Eliquis |
| Merck Sharp & Dohme LLC | $76.49 | 2020-2025 | Capvaxive, Rotateq, Gardasil 9 |
| Astrazeneca Pharmaceuticals LP | $71.68 | 2023-2024 | Farxiga |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $67.85 | 2022-2023 | Quviviq |
| Exact Sciences Corporation | $66.27 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Servier Pharmaceuticals LLC | $59.73 | 2021-2024 | |
| Boston Scientific Corporation | $41.43 | 2025 | Watchman Flx |
| Genzyme Corporation | $33.00 | 2020-2022 | |
| Abbott Laboratories | $30.29 | 2023 | Freestyle Libre 3 |
| Kite Pharma, INC. | $27.03 | 2025 | Yescarta |
| Alexion Pharmaceuticals, INC. | $23.82 | 2019 | |
| Janssen Pharmaceuticals, INC | $18.73 | 2022 | |
| Emd Serono, INC. | $17.58 | 2020 | |
| Mylan Specialty L.P. | $16.79 | 2024 | Yupelri |
| Janssen Biotech, INC. | $15.18 | 2022 | |
| Daiichi Sankyo INC. | $15.13 | 2022 | |
| Phathom Pharmaceuticals, INC. | $14.74 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cary Peterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.